Login to Your Account



One in the Hand, Two in the Bush

To Partner or Not to Partner? That Is the Hep C Question

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, May 7, 2012

Data presented at the 2012 International Liver Congress of the European Association for the Study of the Liver last month showed Gilead Sciences Inc.'s nuc drug GS-7977 works well with Bristol-Myers Squibb Co.'s NS5A inhibitor daclatasvir.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription